Cell and Tissue Banking ( IF 1.4 ) Pub Date : 2023-01-03 , DOI: 10.1007/s10561-022-10063-z
Ramadan Jashari 1 , Vanessa Bouzet 1 , Maria-Josee Alcaraz Blanco 1 , Alison Oleffe 1 , Emilie Lecocq 1 , Stefano Mastrobuoni 1, 2
|
Vascular tissue banking has been carried out in Brussels for over 30 years in compliance with EU and Swiss tissue banking regulations. A total of 2.765 vascular tissue donations were performed in Belgian, French, Netherlands and Suisse transplant centres: 547(20%), 1.013(37%) and 1.205(43%) during the first, second and third periods, respectively. 85% and 18% increase in donations during the second and third decades compared to previous one, were remarkable. Of the 7.066 evaluated vascular tissues, 2.407(227, 921 and 1.259) were discarded (34.1%), whereas 4.659(523, 1.861 and 2.275) accepted (65.9%) during the respective period. Of the 92 donated veins, 44(47.8%) were discarded and 48(52.2%) accepted. Allografts available for clinical application were stored in vapours of liquid nitrogen. A total of 4.636 allografts were delivered and transplanted for cases of infection (58%), critical limb ischaemia (16%) and congenital cardiac surgery (15%). Thirty veins were implanted. The progressive increases in donations of 20%, 37% and 43% and in transplantations of 20.8%, 34.6% and 45% during the first, second and third periods, respectively, were remarkable. Complications were reported after transplantation and these included acute rejection of two femoral arteries one month after transplantation. We conclude that the donation and transplantation of cryopreserved vascular allografts was stable with a progressive increase over time. Allografts were used predominantly for the treatment of infection, limb salvage for critical ischaemia and for neonates and infants with congenital cardiac malformation. Immune related rejection was observed. This should be a subject of future investigation.
中文翻译:

欧洲临床应用的同种异体血管移植:对布鲁塞尔 30 年血管组织库经验的评估
布鲁塞尔的血管组织库已按照欧盟和瑞士组织库法规开展了 30 多年。比利时、法国、荷兰和瑞士移植中心共进行了2.765例血管组织捐献:第一、第二和第三期分别为547例(20%)、1.013例(37%)和1.205例(43%)。与前一个十年相比,第二个和第三个十年的捐款增加了 85% 和 18%,这是引人注目的。在7.066个评估的血管组织中,2.407个(227个、921个和1.259个)被丢弃(34.1%),而4.659个(523个、1.861个和2.275个)在相应时期被接受(65.9%)。92 条捐献静脉中,44 条(47.8%)被丢弃,48 条(52.2%)被接受。可用于临床应用的同种异体移植物储存在液氮蒸气中。共交付并移植了4.636例同种异体移植物,用于感染(58%)、严重肢体缺血(16%)和先天性心脏手术(15%)的病例。植入了三十条静脉。第一、二、三期的捐献量分别增长了20%、37%和43%,移植量分别增长了20.8%、34.6%和45%,令人瞩目。移植后报告了并发症,其中包括移植后一个月两根股动脉的急性排斥反应。我们的结论是,冷冻保存的同种异体血管的捐赠和移植是稳定的,并且随着时间的推移逐渐增加。同种异体移植主要用于治疗感染、严重缺血的保肢以及患有先天性心脏畸形的新生儿和婴儿。观察到免疫相关的排斥反应。这应该是未来调查的一个主题。